Last update June 6, 2020
Immunosuppressant indicated in the prophylaxis of acute renal, cardiac or liver allogeneic transplant rejection.
Oral administration twice a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) makes transfer into breastmilk in significant quantities unlikely.
No problems have been observed in infants breastfed for up to 14 months whose mothers were taking it (Constantinescu 2014).
Its use is authorized in infants from 3 months of age (FDA 2018).
Mycophenolate is considered unsafe during lactation by various medical societies and expert consensus (Hale 2019, Birru 2020, Brown 2017, Briggs 2017, (Shah 2016), Flint 2016, Götestam 2016, Noviani 2016, Butler 2014, Weber 2008, Mahadevan 2006, Østensen 2006, Temprano 2005).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives are preferable (Shah 2016), especially during the neonatal period and in cases of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM